



Issue of Shares

NEW YORK and SYDNEY, Australia, 7 November, 2024 - Beroni Group (OTCQB: BNIGF; NSX: BTG) ("Beroni" or the "Company"), advises that the Company has issued 40,000 ordinary shares to its newly appointed Chief Scientist as incentive shares. The new shares are subject to temporary holding lock until the release of a cleansing prospectus.

-End-

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit www.beronigroup.com.

For more information, please contact us at:

Tel: +61 2 9159 1827

Email: enquiry@beronigroup.com

Website: www.beronigroup.com